CJC-1295 vs Sermorelin: GHRH Analog Comparison

CJC-1295 and Sermorelin are both synthetic analogs of growth hormone-releasing hormone (GHRH), the hypothalamic hormone that tells the pituitary gland to produce and release GH. But they differ dramatically in half-life, dosing frequency, and the nature of the GH release they produce.

Understanding these differences is essential for researchers and clinicians selecting the appropriate GHRH analog for specific protocols — whether the goal is anti-aging optimization, body composition improvement, or recovery support.

For researchers sourcing these compounds, Amino Club provides COA-verified peptides with documented purity testing. Browse peptides →

Sermorelin: The Pioneer GHRH Analog

Sermorelin (GRF 1-29 NH₂) is a 29-amino acid synthetic peptide corresponding to the first 29 amino acids of the 44-amino acid native GHRH molecule. It was FDA-approved in 1997 under the brand name Geref for diagnosing and treating pediatric growth hormone deficiency.¹

Sermorelin binds to the GHRH receptor on pituitary somatotroph cells, stimulating transcription, synthesis, and pulsatile release of endogenous GH. Its half-life is extremely short — approximately 10-20 minutes — meaning its effects are brief, pulsatile, and highly physiological.

Clinical data from the original registration trials showed that sermorelin: increased growth velocity in GH-deficient children, elevated IGF-1 levels to age-appropriate ranges, and maintained normal pituitary-hypothalamic feedback mechanisms (unlike exogenous GH which suppresses them).¹

In adult clinical practice, sermorelin is commonly prescribed by anti-aging and integrative medicine practitioners at doses of 200-300 mcg subcutaneously before bed, leveraging the natural nocturnal GH surge.

CJC-1295: The Engineered Upgrade

CJC-1295 is a 30-amino acid synthetic GHRH analog that exists in two forms:

CJC-1295 without DAC (Mod GRF 1-29)

Also known as Modified GRF 1-29, this version has four amino acid substitutions that improve metabolic stability compared to sermorelin, extending half-life to approximately 30 minutes. It produces GH pulses similar to sermorelin but with slightly greater amplitude and duration. It is typically dosed 2-3 times daily or before bed.

CJC-1295 with DAC

The Drug Affinity Complex (DAC) modification adds a reactive chemical group that allows CJC-1295 to covalently bond with serum albumin after injection. This dramatically extends the functional half-life to approximately 6-8 days, producing sustained GH and IGF-1 elevation with once-weekly dosing.²

A pivotal clinical study by Teichman et al. demonstrated that a single subcutaneous injection of CJC-1295 with DAC produced sustained IGF-1 elevation lasting 6-14 days, with peak IGF-1 increase of 1.5-3x baseline. Multiple doses raised mean IGF-1 by 2x with no evidence of tachyphylaxis.²

Head-to-Head Comparison

Feature	Sermorelin	CJC-1295 (no DAC)	CJC-1295 (with DAC)
Half-Life	10-20 min	~30 min	6-8 days
Dosing Frequency	Daily (before bed)	2-3x daily or nightly	1-2x weekly
GH Pattern	Pulsatile (most physiological)	Pulsatile	Sustained/tonic
IGF-1 Elevation	Moderate	Moderate-High	High (sustained)
FDA History	Approved (1997)	Investigational	Investigational
Clinical Data	Extensive	Moderate	Moderate

Optimal Stacking

Both sermorelin and CJC-1295 are optimally paired with Ipamorelin — a selective GHRP that triggers GH release via the complementary ghrelin pathway. This GHRH + GHRP combination produces synergistic GH amplification (3-6x greater pulses) through a dual-pathway mechanism.³

Sermorelin + Ipamorelin: Best for physiological pulsatile GH release, anti-aging protocols, and long-term use where natural GH patterns are prioritized.

CJC-1295 (w/DAC) + Ipamorelin: Best for sustained IGF-1 elevation, body composition goals, and protocols where dosing convenience is important.

Research Verdict

For anti-aging and longevity:Sermorelin's shorter half-life and physiological pulsatile release pattern more closely mimic natural GH secretion, which many clinicians prefer for long-term health optimization.

For body composition and performance: CJC-1295 with DAC provides stronger, more sustained GH/IGF-1 elevation with greater convenience and compliance due to weekly dosing.

Both are well-tolerated with comparable side effect profiles (mild water retention, occasional headache, transient fatigue).

Sources

Walker, R.F. "Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?" Clinical Interventions in Aging, 2006; 1(4): 307-308.
Teichman, S.L., et al. "Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295." JCEM, 2006; 91(3): 799-805.
Raun, K., et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology, 1998; 139(5): 552-561.

Frequently Asked Questions

What is the difference between CJC-1295 and Sermorelin?

Both are synthetic GHRH analogs that stimulate the pituitary gland to release growth hormone. The key difference is half-life: Sermorelin has a very short half-life of 10-20 minutes, requiring daily or twice-daily injections. CJC-1295 (especially with DAC) has a half-life of 6-8 days, enabling once- or twice-weekly dosing. CJC-1295 also produces more sustained IGF-1 elevation, while Sermorelin produces more physiological, pulsatile GH release.

What is CJC-1295 with DAC vs without DAC?

DAC stands for Drug Affinity Complex — a modification that allows CJC-1295 to bind to serum albumin, dramatically extending its half-life from ~30 minutes (without DAC, also called Modified GRF 1-29) to 6-8 days (with DAC). CJC-1295 with DAC provides sustained GH elevation, while CJC-1295 without DAC (Mod GRF 1-29) provides shorter GH pulses more similar to Sermorelin.

Is Sermorelin FDA-approved?

Sermorelin was FDA-approved in 1997 under the brand name Geref for diagnosing and treating growth hormone deficiency in children. While the branded product was discontinued in 2008 for commercial reasons, sermorelin remains available through compounding pharmacies for off-label clinical use and is one of the most well-characterized GHRH analogs in clinical practice.

Can you combine CJC-1295 and Sermorelin?

This combination is generally not recommended as both compounds target the same GHRH receptor on the pituitary. Using both simultaneously would provide redundant stimulation without meaningful synergistic benefit. Instead, either compound is typically paired with a GHRP (like Ipamorelin) for complementary GH release through the ghrelin pathway.

Which is better for anti-aging: CJC-1295 or Sermorelin?

For anti-aging and longevity protocols, Sermorelin is often preferred by clinicians due to its more physiological GH release pattern (mimicking natural pulsatility) and its longer clinical safety track record. CJC-1295 with DAC is preferred when dosing convenience is important. Both effectively raise IGF-1 to age-appropriate levels when dosed correctly.